.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,141,375

« Back to Dashboard

Details for Patent: 7,141,375

Title:Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor
Abstract: A method is provided for treating solid tumors comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent. In a preferred embodiment the PDGF aptamer is identified using the SELEX process for the Systematic Evolution of Ligands by Exponential enrichment. A method is also provided for reducing the interstitial fluid pressure (IFP) of a solid tumor comprising administering a PDGF aptamer. Finally, a method is provided for increasing the uptake of cytotoxic agents into a tumor comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent.
Inventor(s): Pietras; Kristian (Uppsala, SE), Ostman; Arne (Uppsala, SE), Heldin; Carl-Henrik (Uppsala, SE), Rubin; Kristofer (Uppsala, SE)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Filing Date:Mar 02, 2004
Application Number:10/791,367
Claims:1. A method for treating tumors comprising: a) pre-treating a host having a tumor by administering a therapeutically effective dose of a platelet-derived growth factor (PDGF) aptamer for a predetermined number of days; and b) subsequently administering a therapeutically effective dose of a cytotoxic agent to said host.

2. The method of claim 1 wherein in step b) said cytotoxic agent is administered in combination with said PDGF aptamer.

3. The method of claim 1 wherein said PDGF aptamer is identified according to a method comprising: a) preparing a candidate mixture of nucleic acids; b) contacting the candidate mixture of nucleic acids with PDGF, wherein nucleic acids having an increased affinity to PDGF relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to PDGF, whereby a nucleic acid ligand of PDGF may be identified.

4. The method of claim 1 wherein said PDGF aptamer is: ##STR00001## wherein: U at positions 6, 20 and 30 is 2'-fluoro-2'-deoxyuridine; C at positions 8, 21, 28, and 29 is 2'-fluoro-2'-dcoxycytidine; G at positions 9, 15, 17, and 31 is 2'-O-Methyl-2'-dcoxyguanosine; A at position 22 is 2'-O-Methyl-2'-deoxyadenosine; and wherein PEG spacer= ##STR00002##

5. The method of claim 1 wherein said cytotoxic agent is selected from the group consisting of Bleomycin, Cisplatin, and Pt analogues; Carboplatin and Iproplatin, Cyclophosphamide, Daunorubicin, Doxofluoridine, Doxorubicin, Etoposide, Epirubicin, 5-Flurouracil, Gemcitabine HCL, Ifosfamide, Melphalan, Methotrexate, Mithramycin, Mitomycin C, Mitoxanthrone, Streptozotocin, paclitaxel and docetaxel, Vincristine, Vinblastine, Vindesine, Vinorelbine, Topotecan and CPT-11.

6. A method for increasing the uptake of cytotoxic agents into a tumor comprising: a) pre-treating a host having a tumor by administering a therapeutically effective dose of a platelet-derived growth factor (PDGF) aptamer for a predetermined number of days; and b) subsequently administering a therapeutically effective dose of a cytotoxic agent to said host.

7. The method of claim 6 wherein in step b) said cytotoxic agent is administered in combination with said PDGF aptamer.

8. The method of claim 6 wherein said PDGF aptamer is identified according to a method comprising: a) preparing a candidate mixture of nucleic acids; b) contacting the candidate mixture of nucleic acids with PDGF, wherein nucleic acids having an increased affinity to PDGF relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to PDGF, whereby a nucleic acid ligand of PDGF may be identified.

9. The method of claim 6 wherein said PDGF aptamer is: ##STR00003## wherein: U at positions 6, 20 and 30 is 2'-fluoro-2'-deoxyuridine; C at positions 8, 21, 28, and 29 is 2'-fluoro-2'-dcoxycytidine; G at positions 9, 15, 17, and 31 is 2'-O-Methyl-2'-dcoxyguanosine; A at position 22 is 2'-O-Methyl-2'-deoxyadenosine; and wherein PEG spacer= ##STR00004##

10. The method of claim 6 wherein said cytotoxic agent is selected from the group consisting of Bleomycin, Cisplatin, and Pt analogues; Carboplatin and Iproplatin, Cyclophosphamide, Daunorubicin, Doxofluoridine, Doxorubicin, Etoposide, Epirubicin, 5-Flurouracil, Gemcitabine HCL, Ifosfamide, Melphalan, Methotrexate, Mithramycin, Mitomycin C, Mitoxanthrone, Streptozotocin, paclitaxel and docetaxel, Vincristine, Vinblastine, Vindesine, Vinorelbine, Topotecan and CPT-11.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc